Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-355: pembro + chemo in triple-negative breast cancer

Javier Cortés • 25 May 2020
ASCO 2020
Breast Cancer Pembrolizumab
KEYNOTE-355

Javier Cortés, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, discusses the KEYNOTE-355 study (NCT02819518) to determine the efficacy of pembrolizumab and chemotherapy versus chemotherapy alone in untreated, locally recurrent inoperable or metastatic triple-negative breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Javier Cortés

2:34
ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355
Javier Cortés • 24 Sep 2021
2:48
DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer
Javier Cortés • 24 Sep 2021
2:38
Potential new drugs with activity in metastatic TNBC
Javier Cortés • 12 May 2021
1:21
ESMO Breast 2021 highlights: biomarker updates
Javier Cortés • 12 May 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals